---
schema_version: "secwatch.filing_event.v1"
accession: "0001563880-25-000005"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2025-08-20T23:59:59+00:00"
generated_at: "2026-05-17T11:08:42.562461+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics CFO Lisa Delfini to depart Aug 22; CEO to serve as interim principal financial officer

## Summary
- CFO Lisa Delfini will resign effective August 22, 2025; departure is not due to any disagreement with the company.
- CEO Jennifer L. Good will serve as interim principal financial officer until a permanent CFO is appointed.
- Delfini will receive separation benefits under the Executive Separation Benefits and Retention Plan, subject to a severance and release agreement.
- No details provided on search for permanent CFO or timeline.

## SEC filing metadata
- accession: 0001563880-25-000005
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2025-08-20T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000156388025000005/0001563880-25-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000156388025000005/trvi-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001563880-25-000005
- JSON: https://secwatch.observer/filing/0001563880-25-000005.json
- Plain text: https://secwatch.observer/filing/0001563880-25-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.